ArticleAmerican health & drug benefits2017

Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors.

Rajeev Ayyagari et al.PubMed ↗Full text ↗

No numbers read from the abstract.